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![Tc-99m MDP bone scintigraphy. A 68-year-old women was admitted to the hospital on October 2013 with a mass on the cervical region. An excisional biopsy revealed parathyroid cancer. PET/CT showed multiple hypermetabolic lesions in the skeleton. The patient was treated by combination chemotherapy (including cisplatin and etoposide) plus zoledronic acid with good clinical response. Two years later, she presented with fatigue. Her laboratory results showed severe hypercalcemia and renal failure (serum calcium level 16.6 mg/dL, blood urea nitrogen/creatinine: 32/2.3 mg/dL). The parathormone level was 1859.6 pg/mL. Hydration was performed, calcitonin was prescribed but the hypercalcemia could not be controlled. Tc-99m MDP bone scintigraphy revealed intense radiotracer uptake involving almost the entire skeleton with high bone to soft tissue uptake (A and B). Bilateral kidneys were almost invisible (A and B). These findings are suggestive of 'metabolic superscan'. There was focal radiotracer uptake in several ribs considered as Brown tumors according to CT findings (C and D). Brown tumors represent a reparative cellular process rather than a neoplastic process (1). The increased uptake of radiopharmaceutical by pathologic bone results in reduced phosphate excretion, thereby producing faint renal images on bone scintigraphy. Wiegemann et al. (2) reported that bone resorption, alkaline phosphatase level, and parathyroid hormone activity were not correlated with Tc-99m pyrophosphate uptake by the bone. Malignancies with known super scan in bone scintigraphy include prostate cancer, breast cancer, lung cancer, lymphoma, urinary tract transitional cell carcinoma, nasopharyngeal carcinoma and carcinoma of the colon (3,4,5). Hematologic conditions like leukemia, lymphoma, myelofibrosis, Waldenstrom's macroglobulinemia have also been reported to be associated with super scan. This feature can also be detected in metabolic bone diseases like renal osteodystrophy, Paget's disease and hyperparathyroidism (2)](MIRT-26-116-g1){#f1}

![^18^F-FDG PET/CT demonstrated diffuse and intense hypermetabolism throughout the skeleton (A and B). In FDG PET scan, the faint visualization of the brain, renal cortex, and soft tissue might be the result of extraordinarily high uptake of FDG by skeletal lesions. The presented patient was not on any medications that could have disturbed cerebral glucose metabolism, such as corticosteroids or sedatives](MIRT-26-116-g2){#f2}

![Interestingly the mediastinum, skeletal muscles of the limbs, bowel and especially the brain showed very low FDG uptake on ^18^F-FDG PET/CT. A parathyroid adenoma failed to be detected by FDG PET. A similar article described by Demir et al. (6) in 2007 reported FDG PET and bone scan results in a patient with primary hyperparathyroidism as showing diffusely increased tracer uptake by the skeleton, reflecting metabolic bone disease. However, to the best of our knowledge, superscan secondary to hyperparathyroidism caused by parathyroid carcinoma has not been reported previously and is described herein](MIRT-26-116-g3){#f3}

![The patient underwent parathyroid scintigraphy for detecting a parathyroid focus, after injection of 740 MBq (20 mCi) MIBI. Three focal MIBI uptakes in the low cervical region were considered as functional parathyroid carcinoma recurrence (A and B). These functional lesions were embolized percutaneously with 95% alcohol under ultrasound guidance in two sessions with an amount of 0.8 cc and 1.5 cc, respectively, by an interventional radiologist experienced in ultrasound guided procedures](MIRT-26-116-g4){#f4}
